Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy; Shares Will Rebound
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
UBS Reiterates Buy on Esperion Therapeutics (ESPR) Ahead of FDA Meeting; Sees Meaningful Upside
August 7, 2015 10:46 AM EDTUBS analyst Andrew Peters reiterated his Buy rating and $140 price target on Esperion Therapeutics (NASDAQ: ESPR), which suggests 152% upside from yesterday's close. Comments following in-line Q2 results and comments from the conference call which add color ahead of the FDA meeting.
"2Q15 financial results were in line with expectations, with management focusing the conf. call on addressing recent investor questions on ETC-1002 and regulatory risk," Peters commented. " With the recent pull-back in... More
Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
August 7, 2015 8:30 AM EDTChardan Capital affirms its Sell rating on Esperion (Nasdaq: ESPR) and cuts its price target from $45 to $40 following Q2 results.
Analyst Gbola Amusa commented, Esperion reported 2Q basic and diluted EPS of -$0.55, versus our expectation of -$0.56. A share count of... More
Esperion Therapeutics (ESPR) Tops Q2 EPS by 3c
August 6, 2015 5:05 PM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58).
2015 Financial Outlook
Esperion expects that the net cash used to fund operating activities in 2015 will be approximately $42 million and that its cash and cash equivalents and investment securities available-for-sale will total... More
